Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Latest Biotechnology and Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings, Inc. Stock News

As of July 31, 2026, Iovance Biotherapeutics, Inc. had a $1.8 billion market capitalization, compared to the Biotechnology median of $252.6 million. Iovance Biotherapeutics, Inc.’s stock is up 49.1% in 2026, down 18.4% in the previous five trading days and up 52.43% in the past year.

Currently, Iovance Biotherapeutics, Inc. does not have a price-earnings ratio. Iovance Biotherapeutics, Inc.’s trailing 12-month revenue is $285.6 million with a -123.9% net profit margin. Year-over-year quarterly sales growth most recently was 44.8%. Analysts expect adjusted earnings to reach $-0.564 per share for the current fiscal year. Iovance Biotherapeutics, Inc. does not currently pay a dividend.

As of July 31, 2026, Maravai LifeSciences Holdings, Inc. had a $969.1 million market cap, putting it in the 45th percentile of all stocks. Maravai LifeSciences Holdings, Inc.’s stock is up 102.2% in 2026, down 2.8% in the previous five trading days and up 172.61% in the past year.

Currently, Maravai LifeSciences Holdings, Inc. does not have a price-earnings ratio. Maravai LifeSciences Holdings, Inc.’s trailing 12-month revenue is $204.7 million with a -51.1% net profit margin. Year-over-year quarterly sales growth most recently was 40.3%. Analysts expect adjusted earnings to reach $-0.113 per share for the current fiscal year. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.

How We Compare Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Iovance Biotherapeutics, Inc.	IOVA	F
Maravai LifeSciences Holdings, Inc.	MRVI	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Iovance Biotherapeutics, Inc. has a Value Score of 13, which is Ultra Expensive. Maravai LifeSciences Holdings, Inc. has a Value Score of 16, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to value.

Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. Growth Grades

Company	Ticker	Growth
Iovance Biotherapeutics, Inc.	IOVA	na
Maravai LifeSciences Holdings, Inc.	MRVI	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Iovance Biotherapeutics, Inc. does not have a meaningful Growth Score. Maravai LifeSciences Holdings, Inc. has a Growth Score of 8, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to sustainable growth.

Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Iovance Biotherapeutics, Inc.	IOVA	D
Maravai LifeSciences Holdings, Inc.	MRVI	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Iovance Biotherapeutics, Inc. has a Earnings Estimate Score of 34, which is Negative. Maravai LifeSciences Holdings, Inc. has a Earnings Estimate Score of 78, which is Positive.

The Earnings Estimate Revisions Grade Winner: Maravai LifeSciences Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Maravai LifeSciences Holdings, Inc. has a better Earnings Estimate Revisions Grade than Iovance Biotherapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Maravai LifeSciences Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. Grades

In addition to Estimate Revisions, Value and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings or Inc. Stock?

Overall, Iovance Biotherapeutics, Inc. stock has a Value Score of 13, Growth Score of and Estimate Revisions Score of 34.

Maravai LifeSciences Holdings, Inc. stock has a Value Score of 16, Growth Score of 8 and Estimate Revisions Score of 78.

Comparing Iovance Biotherapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.